A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Oncotelic Inc.
- Study ID
- NCT06079346
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- OT-101 — DRUGOT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
- mFOLFIRINOX — DRUGFolinic acid, 5-FU, Irinotecan, Oxaliplatin
Study Details
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.
Key Dates
- Start date
- May 1, 2024
- Status verified
- May 2024
- Primary completion
- Jun 1, 2026
- Completion
- Jun 1, 2027
Study Design
- Enrollment
- 455 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: OT-101 + mFOLFIRINOXOT-101 IV dosed on Days 4-7 plus mFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
- Placebo Comparator: mFOLFIRINOX OnlymFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
Primary Outcome Measure
Overall Survival (OS) [ Time Frame: 2.5 years ]
Central Contacts
- Cynthia Lee, PhD(650) 635-7024
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Karmanos Cancer Center | Detroit | Michigan | 48201 | Anthony Shields, MD (PRINCIPAL_INVESTIGATOR) |
| Baylor College of Medicine | Houston | Texas | 77030 | Shalini Makawita, MD |
Find similar trials in Detroit, MI
By condition
By specialty
Related Studies
- iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- Pancreatic Cancer Early Detection ConsortiumRecruiting · Arbor Research Collaborative for Health · Phoenix, Arizona